MK 0663 PAGE 121 ETORICOXIB RISK MANAGEMENT PLAN, VERSION 3.2
|
|
- Antonia Floyd
- 6 years ago
- Views:
Transcription
1 MK 0663 PAGE 121 ETORICOXIB VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Epidemiology of a disease provides information on The spread of the disease - in different sets of people - in different regions of the world, The causes and effects associated with the disease, and Control of the disease. Osteoarthritis (OA) is a joint disease that is characterized by breakdown of the cartilage (the tissue that cushions the ends of the bones between joints), bony changes, deterioration of tendons and ligaments, and inflammation of the joint lining in the spine, hands, knees, and hips. Prevalence estimates vary significantly depending on the joint, whether estimates are based on symptoms and/or radiographic damage, and increase significantly with age. Prevalence of hand and knee OA can range from 15% to as high as 70-90%. Certain factors have been shown to be associated with a greater risk of arthritis. Non-modifiable risk factors include ageing, gender (more common in women), genetic predisposition, and low bone density. Modifiable risk factors include excess weight (obesity), joint injuries, joint infections, and occupations associated with repetitive knee bending and squatting. Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis (where certain cells of the immune system attack the joints). RA is a chronic (long-term) disease that causes pain, stiffness, swelling, and limited motion and function of many joints. The small joints in the hands and feet tend to be involved most often. RA affects between 0.3 and 2.0% of the population with women affected two to three times as frequently as men. The prevalence varies among geographic regions/climates and in some specific ethnic groups. Incidence / prevalence increases with age, reaching maximum between 50 and 60 years. Although the cause of RA is unknown, it is generally seen as a result of an interaction between genetic factors and environmental exposures. Non-modifiable risk factors include ageing, gender, and genetic predisposition. Modifiable factors include exposure to hormones (oral contraceptives, hormone replacement therapy), tobacco use, dietary factors, and microbial exposures. Gout is a form of arthritis characterized by intense episodes of painful swelling in single joints, most often in the feet, especially the big toe. Gout occurs when excess uric acid (a normal waste product) collects in the body and crystals deposit in the joints. The prevalence is in the range of %.. It is more commonly seen in men. The prevalence increases sharply with age, starting at ages in both genders. In women, the incidence/prevalence is greatest following menopause. Risk factors for gout include ageing, gender, genetic predisposition, obesity, hypertension, certain medicines, dietary factors, excessive alcohol intake, thyroid disease, hyperlipidemia, diabetes, and kidney disease.
2 MK 0663 PAGE 122 ETORICOXIB Ankylosing Spondylitis is a type of arthritis that primarily affects the spine. It differs from other types of arthritis, because it involves the sites where ligaments and tendons attach to bones. Patients may have inflammation causing pain and stiffness and bone destruction affecting the spine and pelvic joints. Prevalence estimates range from %. A higher incidence and prevalence is seen in men than in women. Higher prevalence and incidence reported in North American and European populations than in other parts of the world. Risk factors for AS include age (17-45 years), gender, genetic predisposition (HLA-B27 gene), and frequent gastrointestinal (GI) infections. Etoricoxib is also used to treat pain associated with dental surgery, including third molar surgery. Third molar extraction is one of the most common procedures performed by oral and maxillofacial surgeons, and most patients have some degree of pain following this procedure. Third molar extraction is more commonly performed in patients younger than 40 years of age (mean age 26-27) and is relatively uncommon in patients 60 years or older. Most patients undergoing the procedure are healthy. Preoperative pain, female gender, older age, anxiety, depression, and patient expectations, have been identified as risk factors associated with dental surgery pain. VI.2.2 Summary of Treatment Benefits Efficacy is the capacity of a drug to produce a desired effect. Etoricoxib is a member of a group of medicines called non-steroidal anti-inflammatory agents (NSAIDS). Etoricoxib is also known as a cyclo-oxygenase-2 (COX-2) inhibitor because it works by blocking this enzyme in the body. COX-2 is involved in the production of mediators of pain and inflammation in response to disease. By blocking the action of COX-2, etoricoxib reduces pain and inflammation. In patients with OA, etoricoxib 60 mg once daily reduced pain and improved patients assessments of disease status. These beneficial effects were observed as early as the second day of therapy and were maintained for up to 52 weeks. In patients with RA, etoricoxib 90 mg once daily improved pain, inflammation and mobility. These beneficial effects were maintained over the 12-week treatment period. In patients experiencing acute attacks of gouty arthritis, etoricoxib 120 mg once daily, over an eight-day treatment period, relieved moderate to extreme joint pain and inflammation that was comparable to indomethacin 50 mg three times daily. Pain relief was observed as early as 4 hours after start of treatment. In patients with AS, etoricoxib 90 mg once daily improved spine pain, inflammation, stiffness and function. The beneficial effects of etoricoxib were observed as early as on the second day of therapy and were maintained throughout the 52-week treatment period. In a study assessing pain following dental surgery, etoricoxib 90 mg was administered once daily for up to 3 days. In the subgroup of patients with moderate pain at baseline, etoricoxib 90 mg demonstrated a pain-relieving effect similar to that of ibuprofen 600 mg and greater than that of paracetamol / codeine 600 mg/60 mg and placebo (a pill without active
3 MK 0663 PAGE 123 ETORICOXIB medicine) as measured by total pain relief over the first 6 hours. Out of every 100 patients treated with the medicines under study, the proportion of patients reporting the use of rescue medicines (pain-killers apart from those under study) within the first 24 hours of dosing was 41 for etoricoxib, 25 for ibuprofen, and 47 for paracetamol / codeine compared to 76 for placebo. VI.2.3 Unknowns Relating to Treatment Benefits Etoricoxib has not been studied and should not be used in patients who: are pregnant or breastfeeding are less than 16 years of age have severe kidney disease have severe liver impairment
4 MK 0663 PAGE 124 ETORICOXIB VI.2.4 Summary of Safety Concerns Important Identified Risks Important identified risks are safety issues or undesirable effects for which there is sufficient proof of an association or link with the use of the medicine of interest. Table 51 provides information on the important identified risks and their preventability. Table 51 Summary of Important Identified Risks Risk What is known Preventability Serious gastrointestinal events/ Serious digestive system events Ulcers, obstruction, bleeding and perforation (formation of holes) in the stomach and small intestine are known risks associated with the use of non-selective non-steroidal anti-inflammatory agents. (NSAIDs that block both COX enzymes, COX-1 and COX-2). They have also been reported to occur with etoricoxib use. Etoricoxib is associated with a lower rate of upper digestive tract events as compared to non-selective non-steroidal anti-inflammatory agents. (NSAIDs that block both COX enzymes, COX-1 and COX- 2). Signs and symptoms of bleeding in the digestive tract are black or tarry stools, blood mixed with stool, weakness, dizziness, shortness of breath, crampy abdominal pain, diarrhoea and paleness. Symptoms of stomach outlet obstruction are repeated episodes of vomiting with large amounts of vomit containing undigested food, a persistent feeling of bloating or fullness, and unexplained weight loss. Stomach or intestinal perforation may lead to peritonitis (infection and inflammation of the lining of the abdomen), which may be life threatening. The most common symptom of peritonitis is the sudden onset of abdominal pain, which gets worse steadily. Patients with a history of such events and those aged above 65 years have a higher risk for these events. Etoricoxib should not be used in patients with active stomach or small intestinal ulcers or active bleeding from these organs. Etoricoxib should be used at the lowest effective dose and for the shortest duration possible. Since ulcers, bleedings and perforations of the stomach and small intestine can occur without any warning patients should understand the importance of periodic follow-ups.
5 MK 0663 PAGE 125 ETORICOXIB Table 51 Summary of Important Identified Risks Risk What is known Preventability Thrombotic cardiovascular events/ Events associated with blood clot formation within blood vessels Heart attack, angina (chest pain), sudden blockage of an artery of the lungs (pulmonary embolism), stroke due to interruption of blood supply to the brain (ischaemic stroke) and sudden death are known risks associated with the use of nonselective non-steroidal anti-inflammatory agents. (NSAIDs that block both COX enzymes, COX-1 and COX-2). They have also been reported to occur with etoricoxib use. Etoricoxib is associated with a similar rate of events of blood clot formation within blood vessels compared to non-selective NSAIDs. Signs and symptoms of angina and heart attack are chest pain or discomfort; pain or discomfort in one or both arms, back, shoulders, neck, jaw, or upper part of the stomach; cold sweats; nausea; lightheadedness; and shortness of breath. Signs and symptoms of pulmonary embolism are sudden shortness of breath; sharp chest pain which gets worse while coughing or breathing; and coughing pink, foamy mucus. Signs and symptoms of ischaemic stroke are sudden numbness or weakness of the face, arm or leg, especially involving one side of the body; sudden confusion; trouble speaking or understanding; loss of vision in one or both eyes; trouble walking; dizziness; loss of balance or coordination; and sudden, severe headache with no known cause. Etoricoxib should not be used by patients who have a disease in which there is plaque formation within the arteries supplying the heart (ischaemic heart disease), limbs (peripheral arterial disease) and / or brain (cerebrovascular disease). Patients with significant risk factors for serious heart diseases (e.g. high blood pressure, presence of excess lipids in the blood (hyperlipidaemia], diabetes and smoking) should only be treated with etoricoxib after careful consideration. Etoricoxib should be used at the lowest effective dose and for the shortest duration possible. Patients having any signs or symptoms of such events should report them promptly to their physicians.
6 MK 0663 PAGE 126 ETORICOXIB Table 51 Summary of Important Identified Risks Risk What is known Preventability Renovascular events: Oedema, hypertension, and CHF /Events related to blood vessels of the kidneys: oedema, high blood pressure and congestive heart failure In patients with impaired blood flow to the kidneys due to any reason, certain mediators maintain the perfusion of the kidneys. Use of non-selective non-steroidal anti-inflammatory agents. (NSAIDs that block both COX enzymes, COX-1 and COX-2).in such patients blocks the production of these compensatory mediators and compromises blood flow to the kidneys. This leads to impairment of kidney function. Impairment of blood flow to the kidneys and kidney function may lead to fluid build-up in the legs and feet (oedema), high blood pressure and congestive heart failure. Patients at risk of such events are those with pre-existing impaired kidney function, heart failure or oedema. Signs and symptoms of oedema are swelling of the feet, ankles and legs. People with high blood pressure may have no signs and symptoms. In some people, there may be dull headaches, dizzy spells and more nosebleeds than normal. Signs and symptoms of congestive heart failure are shortness of breath, oedema of the legs and feet, weight gain, palpitations, getting tired easily, and feeling weak and dizzy. Etoricoxib should not be used in patients with advanced kidney impairment, persistent uncontrolled high blood pressure and moderate and severe congestive heart failure. Etoricoxib should be used at the lowest effective dose and for the shortest duration possible. Blood pressure should be monitored frequently in patients on etoricoxib. Patients having any signs or symptoms of oedema, high blood pressure and congestive heart failure should report them promptly to their physicians.
7 MK 0663 PAGE 127 ETORICOXIB Table 51 Summary of Important Identified Risks Risk What is known Preventability Hypersensitivity-related events and serious skin reactions /Allergic reactions and serious skin reactions Allergic reactions can occur with any medicine and are known to occur with non-selective non-steroidal anti-inflammatory agents. (NSAIDs that block both COX enzymes, COX-1 and COX- 2). Serious allergic reactions, such as anaphylactic reactions and angioedema, may also occur. Anaphylactic reaction is a whole body reaction that develops suddenly. Symptoms of anaphylaxis are difficulty breathing, wheezing, coughing, difficulty swallowing, swelling of the throat, low blood pressure, hives, itchiness and rash. In angioedema, there is swelling of the deeper layer of the skin, and the lining of the throat and intestines. Swelling of the eyes, face, lips, tongue, throat and bowels may occur. In severe cases, there may be difficulty breathing or swallowing. Serious skin reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, may occur; however, these are very rare. In Stevens-Johnson syndrome and toxic epidermal necrolysis, the outermost layer of the skin (epidermis) separates from the adjacent layer (dermis) because of an allergic reaction. Stevens-Johnson syndrome is the milder form of the two. Signs and symptoms of Stevens-Johnson syndrome and toxic epidermal necrolysis are flulike symptoms, muscle and joint pain, swelling of the tongue and / or face, a red or purple burning skin rash that spreads, blisters on the skin and mucous membranes (such as in the eyes, nose and mouth), and shedding (sloughing) of the skin. Etoricoxib should not be used by people who are allergic to aspirin or other NSAIDs, including other COX-2 inhibitors. Patients should be alert to the signs and symptoms of allergic reactions and serious skin reactions and visit their doctor immediately, should these occur. Etoricoxib should be discontinued at the first appearance of skin rash, ulcers in the mouth or nose, or any other signs of allergy. Important Potential Risks Important potential risks are the safety issues or undesirable effects for which there is some basis for suspicion of a link with the use of the medicine of interest, but this association has not been confirmed. There are no important potential risks with the use of etoricoxib.
8 MK 0663 PAGE 128 ETORICOXIB Missing Information Important missing information is the information about the safety of a medicine or pill which is not available at the time of submission of a particular risk management plan. Examples of missing information include populations not studied (e.g. pregnant women or patients with severe renal impairment) or where there is a high likelihood of off-label use (pill used for indication other than what it is approved for). Table 52 provides important missing information with the medicinal product. Table 52 Summary of Important Missing Information Missing information What is known Use during pregnancy and breastfeeding Etoricoxib should not be used by pregnant and breastfeeding women. Use of etoricoxib and other non-selective non-steroidal anti-inflammatory agents. (NSAIDs that block both COX enzymes, COX-1 and COX-2) during pregnancy has the potential to cause premature closure of the ductus arteriosus and absence of effective uterine contractions during labour. Use in children and adolescents (patients less than 16 years of age) The ductus arteriosus is a normal blood vessel in an unborn child that connects two major arteries, the aorta and the lung artery, and carries blood away from the heart in the developing baby. Premature closure of the ductus arteriosus may result in right heart failure and oedema in the foetus, which may even result in death of the baby. Etoricoxib should not be used in patients less than 16 years of age, as it has not been studied in patients of this age group. Use in patients with renal insufficiency/use in patients with advanced kidney impairment Use in patients with hepatic impairment/use in patients with severe liver impairment Etoricoxib has not been studied in patients who have severe kidney impairment and should not be used in such patients. Etoricoxib has not been studied in patients who have severe liver impairment and should not be used in such patients. VI.2.5 Summary of Risk Minimization Measures by Safety Concern All medicines have a Summary of Product Characteristics (SmPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimizing them. An abbreviated version of this in lay language is provided in the form of the Package Leaflet (PL). The measures in these documents are known as routine risk minimization measures. This medicine has no additional risk minimization measures.
9 MK 0663 PAGE 129 ETORICOXIB VI.2.6 VI Planned Post-Authorization Development Plan List of Studies in Post-Authorization Development Plan Some studies are conducted after a medicine has been approved for general use. These studies are conducted with the aim of further gaining information that helps in assessing potential and unexpected serious risks associated with the use of the medicine. Interim results are obtained while the study is in progress, before the completion of the study, whereas final results are obtained after the completion of the study. Table 53 List of Studies in Post-Authorization Development Plan Study / Activity Objectives Safety Concerns Addressed Status Etoricoxib Prescribing To quantify whether the risk Serious Patterns and Adverse minimization measures are gastrointestinal Events of Interest effectively communicating events during Etoricoxib important risk information to Thrombotic Treatment HCPs and to determine the cardiovascular in UK Primary Care incidence of adverse events in events (CPRD) (Observational the target population under Renovascular study, Category 3) marketed use in the UK. events A nested case-control Describe the use of etoricoxib Serious PASS of etoricoxib and and the characteristics of gastrointestinal other anti-inflammatory those who use it for AS in the events therapies in a cohort of UK, France, and Germany Thrombotic patients with AS in the Assess the safety profile of Cardiovascular UK, France, and etoricoxib relative to other events Germany NSAIDs Renovascular (Observational study, events Category 3) Post-authorization Describe the use of etoricoxib Serious Ongoing safety study: Safety and thecharacteristics of those gastrointestinal Data on Etoricoxib who use it for AS/SpA in events from Swedish Sweden Thrombotic Registries of Assess the safety profile of cardiovascular Spondyloarthropathy / etoricoxib relative to other events Ankylosing Spondylitis NSAIDs and non-use Renovascular Patients (Observational events study, Category 3) Understanding the use Off label use for Ongoing of etoricoxib in patients dental pain with dental pain including use in (Observational study, children under 16 Category 3) To describe dispensed etoricoxib prescribed by dentists including the associated dental procedures and, patient demographics To describe off-label use by dentists in patients - less than 16 years of age - with doses >90 mg/day To describe the duration of use / number of tablets dispensed Date for Submission of Interim / Final Reports (Target Dates) Ongoing Updated 2Q2014: The MAH will continue to update the study annually until 2017 Ongoing Updated 3Q2014: The MAH will continue to update this study annually until 2017 First report submitted 3Q2014. Final results expected 2016 Report expected to be submitted 2017
10 MK 0663 PAGE 130 ETORICOXIB VI Studies which are a Condition of the Marketing Authorization There are no studies that are a condition to the marketing authorization. VI.2.7 Table 54 Summary of Changes to the Risk Management Plan Over Time Major Changes to the Risk Management Plan RMP version Date Safety concerns Comment JUN-2011 No new safety concerns have been identified in this updated RMP 3.0/ MAY-2015 No new safety concerns have been identified in this updated RMP To support the filing for an acute pain indication (dental pain), a revised and updated RMP was submitted. To support the filing for a postapproval commitment as a followup measure (FUM) for Protocol 107 (etoricoxib 60 and 90 mg) monitoring the efficacy and safety in the Rheumatoid Arthritis, Development Programme, a revised and updated RMP was submitted. To support the filing for a postapproval commitment as a followup measure (FUM) for Protocol 108 (etoricoxib 60 and 90 mg) monitoring the efficacy and safety in Ankylosing Spondylitis patients, a revised and updated RMP was submitted.
Elements for a Public Summary. Overview of Disease Epidemiology. Epidemiology of a disease provides information on
VI.2 VI.2.1 PAGE 123 Elements for a Public Summary Overview of Disease Epidemiology Epidemiology of a disease provides information on The spread of the disease - in different sets of people - in different
More informationRisk Management Plan Etoricoxib film-coated tablets
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis (OA): OA is a condition in which the cartilage of the joints is broken down. This causes stiffness, pain and leads
More informationEtoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets 23.5.2016, Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Etoricoxib STADA 30 mg film-coated
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: , VERSION 1
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: 15-5-2015, VERSION 1 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Musculoskeletal pain: Musculoskeletal
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis Osteoarthritis is the most common type of joint disease. It represents a group of conditions that result in changes
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other
More informationSummary of the risk management plan (RMP) for Kyprolis (carfilzomib)
EMA/639793/2015 Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) This is a summary of the risk management plan (RMP) for Kyprolis, which details the measures to be taken in order to
More informationSummary of the risk management plan (RMP) for Clopidogrel/Acetylsalicylic acid Teva (clopidogrel / acetylsalicylic acid)
EMA/411850/2014 London, 28 July 2014 Summary of the risk management plan (RMP) for (clopidogrel / acetylsalicylic acid) This is a summary of the risk management plan (RMP) for, which details the measures
More informationPHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET
PROPOSED PATIENT INFORMATION LEAFLET FOR PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET SCHEDULING STATUS S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM PHARMA DYNAMICS CLOPIDOGREL
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains
More information08-15 ETORIA SPIMACO
08-15 ETORIA SPIMACO 60 mg, 90 mg & 120 mg Film-coated Tablets Etoricoxib 1. WHAT Etoria IS AND WHAT IT IS USED FOR Etoria is one of a group of medicines called selective COX-2 inhibitors. These belong
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Etoricoxib Orion 30 mg film-coated tablets Etoricoxib Orion 60 mg film-coated tablets Etoricoxib Orion 90 mg film-coated tablets Etoricoxib Orion 120 mg film-coated
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Coronary artery disease and as anticoagulant (inhibiting the clotting of the blood) in patients undergoing surgery to treat blockages
More informationSummary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine)
EMA/674705/2014 Summary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Lilly which details the measures to be taken
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Etoricoxib Mylan 30 mg, filmomhulde tabletten Etoricoxib Mylan 60 mg, filmomhulde tabletten Etoricoxib Mylan 90 mg, filmomhulde tabletten Etoricoxib Mylan 120
More informationARCOXIA. Etoricoxib 30 mg, 60 mg, 90 mg & 120 mg tablets
New Zealand Consumer Medicine Information ARCOXIA Etoricoxib 30 mg, 60 mg, 90 mg & 120 mg tablets What is in this leaflet Please read this leaflet carefully before you start using ARCOXIA. This leaflet
More informationPatient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol
Patient leaflet: Information for the user Paracetamol Galpharm 500mg tablets paracetamol [For medicines available only on prescription:] Read all of this leaflet carefully before you start taking this
More informationAmlodipine and Celecoxib
PATIENT & CAREGIVER EDUCATION Amlodipine and Celecoxib Warning This drug may raise the chance of heart and blood vessel side effects like heart attack and stroke. If these happen, they can be deadly. The
More informationSummary of the risk management plan (RMP) for Duloxetine Mylan (duloxetine)
EMA/281284/2015 Summary of the risk management plan (RMP) for Duloxetine Mylan (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Mylan, which details the measures to be taken
More informationSunitinib. Other Names: Sutent. About This Drug. Possible Side Effects. Warnings and Precautions
Sunitinib Other Names: Sutent About This Drug Sunitnib is used to treat cancer. It is given orally (by mouth). Possible Side Effects Headache Tiredness and weakness Soreness of the mouth and throat. You
More informationNEOFEN 60 mg suppository
PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationNORVASC 5 mg and 10 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER NORVASC 5 mg and 10 mg tablets AMLODIPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which
More informationRHEUMATOLOGY PATIENT HISTORY FORM
!! RAMOS RHEUMATOLOGY, PC RHEUMATOLOGY PATIENT HISTORY FORM Date: / / NAME: Birthdate: / / Last First M. I. Age: Sex: F M Marital status: Never married Married Divorced Separated Widowed Partnered/significant
More informationInlyta (axitinib) for Kidney Cancer
Inlyta (axitinib) for Kidney Cancer Inlyta is a medication used to treat advanced kidney cancer in adults when one prior drug treatment for this disease has not worked Dosage: 5mg taken twice a day How
More informationPackage leaflet: Information for the patient. Melox 10 mg/ml solution for injection meloxicam
Package leaflet: Information for the patient Melox 10 mg/ml solution for injection meloxicam Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationSummary of the risk management plan (RMP) for Moventig (naloxegol)
EMA/611606/2014 Summary of the risk management plan (RMP) for Moventig (naloxegol) This is a summary of the risk management plan (RMP) for Moventig, which details the measures to be taken in order to ensure
More informationFor males: use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods.
PATIENT INFORMATION INLYTA (in-ly-ta) (axitinib) tablets Read this Patient Information before you start taking INLYTA and each time you get a refill. There may be new information. This information does
More informationEloxatin Oxaliplatin concentrated solution for injection
Eloxatin Oxaliplatin concentrated solution for injection Consumer Medicine Information Please read this leaflet before you are given this medicine. What is in this leaflet This leaflet answers some common
More informationSummary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine)
EMA/450483/2015 Summary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Zentiva, which details the measures to be
More informationRABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Flarin 200 mg Soft Capsules Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER Flarin 200 mg Soft Capsules Ibuprofen Read all of this leaflet carefully before you start taking this product. This medicine is available without prescription.
More informationEMEA PUBLIC STATEMENT ON PARECOXIB SODIUM (Dynastat/Rayzon/Xapit) RISK OF SERIOUS HYPERSENSITIVITY AND SKIN REACTIONS
The European Agency for the Evaluation of Medicinal Products Post-authorisation evaluation of medicines for human use London, 22 October 2002 EMEA/25175/02 EMEA PUBLIC STATEMENT ON PARECOXIB SODIUM (Dynastat/Rayzon/Xapit)
More informationYour treatment with XELJANZ
Your treatment with XELJANZ (tofacitinib citrate) THIS BROCHURE HAS BEEN PRODUCED FOR PATIENTS WHO HAVE BEEN PRESCRIBED XELJANZ. BEFORE USING XELJANZ, PLEASE REVIEW THE PACKAGE LEAFLET FOR THIS MEDICINAL
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationDiclofenac, Version 1.2. Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology It has been estimated that one in five adults suffer from pain worldwide, and one in ten adults are diagnosed with pain each year.
More informationSULFASALAZIN 500mg enteric-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SULFASALAZIN 500mg enteric-coated tablets SULFASALAZINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a
More informationPATIENT INFORMATION LEAFLET CARZIN XL
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: 4 mg film coated tablets. Read all of this leaflet carefully before you start taking. Keep this leaflet. You may need to read it
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr SYLVANT pronounced SILL-vant siltuximab for injection Read this carefully before you start taking SYLVANT and each
More informationGARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant
SWISS SUMMARY OF ACTIVITIES IN THE RISK MANAGEMENT PLAN FOR GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant Active Substance: Human Papillomavirus 9-valent Vaccine, Recombinant MAH / MAA
More informationPackage Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol
Package Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nevirapine is used for antiretroviral combination therapy of Human Immunodeficiency Virus (HIV) infection. Human immunodeficiency
More informationREDUCE THE HURT REDUCE THE HARM
IF YOU HAVE OSTEOARTHRITIS (OA) OR RHEUMATOID ARTHRITIS (RA) REDUCE THE HURT AND REDUCE THE HARM DUEXIS reduces the risk of developing stomach ulcers for patients who are taking ibuprofen for OA/RA INDICATIONS
More informationRisk Management Plan Summary
Risk Management Plan Summary TREMFYA (guselkumab) 100 mg/ml pre-filled syringe Document Version: 1.0 (11.07.2018) Based on EU RMP version 1.2 Marketing authorization holder: Janssen-Cilag AG, Gubelstr.
More informationSummary of the risk management plan (RMP) for Nivolumab BMS (nivolumab)
EMA/359171/2015 Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab) This is a summary of the risk management plan (RMP) for Nivolumab BMS, which details the measures to be taken in
More informationOlumiant. (baricitinib) 2 mg and 4 mg, film-coated tablets. Summary of Risk Management Plan (RMP) Version 2.0, Page 1
Olumiant (baricitinib) 2 mg and 4 mg, film-coated tablets Summary of Risk Management Plan (RMP) Version 2.0, 16-04-2018 Page 1 Summary of the risk management plan (RMP) for Olumiant (baricitinib) The Risk
More informationEpiramat 25mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Epiramat 25mg Film-coated Tablets TOPIRAMATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which
More informationSummary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion
Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO Avelumab 200 mg/10 ml Concentrate for Solution for Infusion Marketing Authorisation Number 66380 Marketing Authorisation Holder:
More informationSINGULAIR JUNIOR 5mg chewable tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SINGULAIR JUNIOR 5mg chewable tablets MONTELUKAST This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationRead all of this leaflet carefully because it contains important information for you.
Nurofen Plus Tablets Ibuprofen 200mg, Codeine Phosphate Hemihydrate 12.8mg ADVANCED DUAL ACTION FOR POWERFUL RELIEF Read all of this leaflet carefully because it contains important information for you.
More informationBISOLVON Chesty Forte.
New Zealand Consumer Medicine Information BISOLVON Chesty Forte Tablets 8 mg Bromhexine hydrochloride What is in this leaflet This leaflet answers some common questions about BISOLVON Chesty Forte. It
More informationPart VI: Summary of the risk management plan by product
Version 1.3, 28-Dec-2015 Risk Management Plan of a fixed combination of Dexketoprofen trometamol and Tramadol hydrochloride (oral formulation) Part VI: Summary of the risk management plan by product VI.1
More informationMethotrexate. About This Drug. Possible Side Effects. Warnings and Precautions
Methotrexate About This Drug Methotrexate is used to treat cancer. This drug is given in the vein (IV). Possible Side Effects Soreness of the mouth and throat. You may have red areas, white patches, or
More informationPatient Information Leaflet UNITED KINGDOM Feldene IM Intramuscular Injection 20mg/ml piroxicam
Patient Information Leaflet UNITED KINGDOM Feldene IM Intramuscular Injection 20mg/ml piroxicam Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need
More information(sunitinib malate) for Kidney Cancer
Sutent (sunitinib malate) for Kidney Cancer Sutent is a medication used to treat adult patients with kidney cancer that has been surgically removed and at high risk of recurrence, or advanced kidney cancer
More informationATORIS 10, 20, 40 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER ATORIS 10, 20, 40 mg film-coated tablets ATORVASTATIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationVI.2. ELEMENTS FOR A PUBLIC SUMMARY
VI.2. ELEMENTS FOR A PUBLIC SUMMARY VI.2.1 Overview of Disease Epidemiology COCs (Combined Oral Contraceptives) containing DRSP-EE (Drospirenone- Ethinylestradiol) are indicated for the prevention of pregnancy
More informationMedical Questionnaire
MEDICIS Health Testing Center Avenue de Tervueren 236 115 Bruxelles Tel : 2/762.5.44 Medical Questionnaire Name :. Maiden name : First name :. Sex :. Address :...... Phone (private) : Office :. Date of
More informationRisk Management Plan
Management Plan Active substance: VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Hypertension is generally defined as blood pressure higher than 140/90 mmhg. Hypertension may
More informationSummary of the risk management plan (RMP) for Opdivo (nivolumab)
EMA/285771/2015 Summary of the risk management plan (RMP) for Opdivo (nivolumab) This is a summary of the risk management plan (RMP) for Opdivo, which details the measures to be taken in order to ensure
More informationFor the Patient: USMAVFIPI
For the Patient: USMAVFIPI Other Names: First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced F =
More informationRELISTOR. Methylnaltrexone bromide, Subcutaneous solution for injection. Consumer Medicine Information
RELISTOR Methylnaltrexone bromide, Subcutaneous solution for injection Consumer Medicine Information What is in this leaflet? This leaflet answers some common questions about RELISTOR. It does not contain
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Indication: Treatment of blood clots Blood clots in the large veins of the legs, known as deep vein thrombosis (DVT), are a common
More informationWhat do I need to tell my doctor BEFORE I take this drug?
PATIENT & CAREGIVER EDUCATION Pembrolizumab Brand Names: US Keytruda Brand Names: Canada Keytruda What is this drug used for? It is used to treat cancer. What do I need to tell my doctor BEFORE I take
More informationSummary of the risk management plan (RMP) for Portrazza (necitumumab)
EMA/33513/2016 Summary of the risk management plan (RMP) for Portrazza (necitumumab) This is a summary of the risk management plan (RMP) for Portrazza, which details the measures to be taken in order to
More informationARCOXIA Etoricoxib (pronounced ee-tor-ee-cox-ib)
ARCOXIA Etoricoxib (pronounced ee-tor-ee-cox-ib) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about ARCOXIA. It does not contain all the available information.
More informationNAKLOFEN 50 mg Suppositories
PACKAGE LEAFLET: INFORMATION FOR THE USER NAKLOFEN 50 mg Suppositories DICLOFENAC SODIUM This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More information*542686* How severe is the problem? mild moderate severe Is it getting better or worse? Better Worse Same over the last hours days weeks months
*542686* Referring Doctor Name: Specialty: City: State: Primary Doctor Name: Specialty: City: State: Instructions: On the body drawing below, please show where you feel pain at this time. Please mark only
More informationPRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic
0 PRODUCT MONOGRAPH FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION Anti-inflammatory, Analgesic INFORMATION FOR THE PATIENT FLOCTAFENINE, which has been prescribed to you
More informationAddress City State Zip. Home Phone Cell Work. (For SHPT use only) Emergency Contact Phone
Somerset Hills Physical Therapy, PC 180 Mount Airy Road, Suite 103 Basking Ridge, NJ 07920 Phone (908) 766-1407 Fax (908) 953-8454 wwwsomersethillsptcom Patient Information: Name Sex M F Date of Birth
More informationJUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION
JUST FOR KIDS For children ages 6-17 with moderately to severely active Crohn s disease or ulcerative colitis (UC) who haven t responded well to other therapies SELECTED IMPORTANT SAFETY INFORMATION REMICADE
More informationEU RISK MANAGEMENT PLAN (EU RMP)
EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and
More informationImportant safety information to minimise the risk of immune-related adverse reactions
Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.
More informationMEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use
MEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use If you are taking PegIntron with REBETOL (ribavirin) with or without an approved hepatitis C virus (HCV)
More informationAmarillo Surgical Group Doctor: Date:
Office Visit Information (General Surgery) Amarillo Surgical Group Doctor: Date: Patient s Information Name: Last First Middle Social Security #: Date of Birth: Age Gender: [ Male / Female ] Marital Status:
More informationNALGESIN NALGESIN S 275 mg Film-coated tablets NALGESIN F 500 mg Film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER NALGESIN NALGESIN S 275 mg Film-coated tablets NALGESIN F 500 mg Film-coated tablets NAPROXEN This leaflet is a copy of the Summary of Product Characteristics
More informationIf you have any concerns about taking this medicine, ask your doctor or pharmacist.
EZETROL ezetimibe 10 mg tablet What is in this leaflet This leaflet answers some common questions about EZETROL. It does not contain all the available information. It does not take the place of talking
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Nicorandil 10 mg Tablets Nicorandil 20 mg Tablets nicorandil
PACKAGE LEAFLET: INFORMATION FOR THE USER Nicorandil 10 mg Tablets Nicorandil 20 mg Tablets nicorandil Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationCOMPOSITION: Each film-coated tablet contains 500mg mefenamic acid. Also includes sunset yellow E110. See leaflet for further information.
Mefac 500mg Film-coated Tablets Mefenamic acid 100 Film-coated Tablets PA Holder: Rowa Pharmaceuticals Ltd., Bantry Co. Cork, Ireland PA 74/15/2 Marketed by: Rowex Ltd., Bantry, Co. Cork, Ireland COMPOSITION:
More informationDabigatran (Pradaxa )
What is dabigatran (Pradaxa )? Dabigatran is also called Pradaxa Dabigatran (Pradaxa ) is used to reduce the risk of blood clots and stroke in people with an abnormal heart rhythm known as atrial fibrillation,
More informationEzetimibe Sandoz Ezetimibe 10 mg tablet
Consumer Medicine Information Ezetimibe Sandoz Ezetimibe 10 mg tablet WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Ezetimibe Sandoz. It does not contain all the available information.
More informationNAKLOFEN SR 100 mg Prolonged-released tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER NAKLOFEN SR 100 mg Prolonged-released tablets DICLOFENAC SODIUM This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationIbuprofen 3 Months Plus 100 mg/5 ml Suspension Strawberry Flavour
Information for the user Ibuprofen 3 Months Plus 100 mg/5 ml Suspension Strawberry Flavour Read all of this leaflet carefully because it contains important information for you. This medicine is available
More informationWhat do I need to tell my doctor BEFORE I take this drug?
PATIENT & CAREGIVER EDUCATION Durvalumab Brand Names: US Imfinzi Brand Names: Canada Imfinzi What is this drug used for? It is used to treat cancer in the bladder or urinary tract. It is used to treat
More informationPronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Pronaxen 250 mg tablet OTC 25.9.2015, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Pronaxen 250 mg is indicated for
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. PRINIVIL (lisinopril tablets, Merck Standard)
44 READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION PRINIVIL (lisinopril tablets, Merck Standard) Read this carefully before you start taking PRINIVIL and each time
More informationDexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.
Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationPatient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR
Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any
More informationMEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill.
MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill. There may be new information. This Medication Guide does not
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationPregabalin Aristo Version: RMP-Pregabalin0
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised by recurring seizures (or fits). It is one
More informationPatient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension
Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This
More informationSummary of the risk management plan (RMP) for Kengrexal (cangrelor)
EMA/78859/2015 Summary of the risk management plan (RMP) for Kengrexal (cangrelor) This is a summary of the risk management plan (RMP) for Kengrexal, which details the measures to be taken in order to
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Human immunodeficiency virus (HIV) is a virus that attacks your body s natural defense system and causes acquired immunodeficiency
More informationPackage leaflet: Information for the user. Burinex 5 mg Tablets bumetanide
Package leaflet: Information for the user Burinex 5 mg Tablets bumetanide Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep
More informationCapecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions
Capecitabine Other Names: Xeloda About This Drug Capecitabine is used to treat cancer. It is given orally (by mouth). Possible Side Effects Tired and weakness Loose bowel movements (diarrhea) Nausea and
More informationCLOPIDOGREL/ASPIRIN ACTAVIS 75/100 Film-Coated Tablets contains the active ingredients clopidogrel and aspirin
ACTAVIS 75/100 Film-Coated Tablets contains the active ingredients clopidogrel and aspirin Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about ACTAVIS
More information